Read more

November 04, 2022
8 min watch
Save

Factors predict compliance with payer-led oncology clinical pathways

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A study presented at this year’s ASCO Quality Care Symposium examined predictors of compliance with payer-led oncology clinical pathways.

The study included patients with one of several malignancies — including melanoma, breast cancer, lung cancer or colorectal cancer — treated in the first-line setting for metastatic disease.

“These findings would be of interest to policymakers focused on value-based cancer care,” Samyukta Mullangi, MD, MBA, third-year fellow in medical oncology at Memorial Sloan Kettering Cancer Center, and colleagues concluded.

In this video, Healio spoke with Mullangi about the study results and their potential implications.